New CEO aims to future-proof Incyte Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 27 June, 2025

sponsored by Oncology Drugs to Watch: Top takeaways from ASCO 2025 Clarivate oncology experts deliver clear, strategic insights on 13 major drugs from ASCO 2025. Learn what the latest data means for the future of cancer treatment and drug development. Download the report

presented by Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

news A dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint Alphabet’s Calico inks $25M licensing deal for Mabwell’s IL-11 programs Peer Review Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio Gilead stops RSV antiviral trials after low incidence rates during recent season

Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Supply chain strategy just got more complicated — is your manufacturing model still viable? Trade tensions, policy shifts, and geopolitical uncertainty have biopharma executives rethinking manufacturing and distribution. How are the experts doing it now? Find out — get your spot today.

ENDPOINTS PHARMA Debate on a long-scrutinized vaccine ingredient consumes CDC panel in its second day •  Watch Post-Hoc Live: A conversation about ACIP and the future of vaccines Judge says CVS Caremark owes $95M in false claims case Ex-CBER chief Marks criticizes how FDA crafted its new Covid vaccine framework Medicare drug spending will slow due to IRA price negotiations, CMS economists predict

in case you missed it 1. Altimmune posts mixed results for incretin drug in MASH; stock is halved 2. Vor Bio bounces back with autoimmune drug pact, $175M private placement 3. Novartis strikes cardiovascular discovery deal with Flagship’s ProFound 4. Opus, Viatris say presbyopia drug succeeds in Phase 3 5. ‘It’s heartbreaking’: Bad cancer drugs shipped to more than 100 countries TBIJ 6.